AstraZeneca: positive data in certain liver cancers
(CercleFinance.com) - AstraZeneca announced that a phase III trial showed that a high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically and clinically significant overall survival (OS) benefit over sorafenib as first-line treatment for patients with certain unresectable hepatocellular carcinomas (HCC).
Called STRIDE, this combination regimen of tremelimumab and Imfinzi demonstrated a favourable safety profile and no increase in liver toxicity.
In addition, treatment with Imfinzi alone demonstrated a non-inferior OS to sorafenib with a numerical trend in favour of Imfinzi and an improved tolerability profile compared to sorafenib.
STRIDE strengthens the patient's immune system against liver cancer, aiming to maximise long-term survival with minimal side effects.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Called STRIDE, this combination regimen of tremelimumab and Imfinzi demonstrated a favourable safety profile and no increase in liver toxicity.
In addition, treatment with Imfinzi alone demonstrated a non-inferior OS to sorafenib with a numerical trend in favour of Imfinzi and an improved tolerability profile compared to sorafenib.
STRIDE strengthens the patient's immune system against liver cancer, aiming to maximise long-term survival with minimal side effects.
Copyright (c) 2021 CercleFinance.com. All rights reserved.